Cell and gene therapies (CGTs) are progressively entering into clinical practice in different parts of the world. The International Society for Cell & Gene Therapy (ISCT), a global scientific society, has been committed since 1992 to supporting and developing knowledge on clinical applications of CGTs. Considering the number of products that have been progressively approved and, in some cases, withdrawn in recent years, the ISCT would like to present a brief annual report on CGTs with marketing authorization (MA) in different regions. This article reflects the dynamic momentum around authorized CGTs coinciding with the parallel increase of unproven approaches where cells are delivered without appropriate and rigorous scientific and regulatory assessment and authorization. This is intended to be a living document with a yearly update linked to a dedicated section of the ISCT website for faster adjustments. The aim is to ultimately inform, by periodic snapshots, the scientific community, healthcare stakeholders and patient associations on authorized CGT products as a way to increase communication around the approved therapeutic approaches charged with heightened expectations.

Cell, tissue and gene products with marketing authorization in 2018 worldwide / Cuende, N.; Rasko, JOHN E. J.; Koh, MICKEY B. C.; Dominici, M.; Ikonomou, L.. - In: CYTOTHERAPY. - ISSN 1465-3249. - 20:11(2018), pp. 1401-1413. [10.1016/j.jcyt.2018.09.010]

Cell, tissue and gene products with marketing authorization in 2018 worldwide

DOMINICI, M.;
2018

Abstract

Cell and gene therapies (CGTs) are progressively entering into clinical practice in different parts of the world. The International Society for Cell & Gene Therapy (ISCT), a global scientific society, has been committed since 1992 to supporting and developing knowledge on clinical applications of CGTs. Considering the number of products that have been progressively approved and, in some cases, withdrawn in recent years, the ISCT would like to present a brief annual report on CGTs with marketing authorization (MA) in different regions. This article reflects the dynamic momentum around authorized CGTs coinciding with the parallel increase of unproven approaches where cells are delivered without appropriate and rigorous scientific and regulatory assessment and authorization. This is intended to be a living document with a yearly update linked to a dedicated section of the ISCT website for faster adjustments. The aim is to ultimately inform, by periodic snapshots, the scientific community, healthcare stakeholders and patient associations on authorized CGT products as a way to increase communication around the approved therapeutic approaches charged with heightened expectations.
24-ott-2018
20
11
1401
1413
Cell, tissue and gene products with marketing authorization in 2018 worldwide / Cuende, N.; Rasko, JOHN E. J.; Koh, MICKEY B. C.; Dominici, M.; Ikonomou, L.. - In: CYTOTHERAPY. - ISSN 1465-3249. - 20:11(2018), pp. 1401-1413. [10.1016/j.jcyt.2018.09.010]
Cuende, N.; Rasko, JOHN E. J.; Koh, MICKEY B. C.; Dominici, M.; Ikonomou, L.
File in questo prodotto:
File Dimensione Formato  
PDF2_Cuende N et al. Cell Therapy with MA 2018 .pdf

accesso aperto

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 763.87 kB
Formato Adobe PDF
763.87 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1168911
Citazioni
  • ???jsp.display-item.citation.pmc??? 34
  • Scopus 68
  • ???jsp.display-item.citation.isi??? 69
social impact